| Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer J Zhao, S Ning, W Lou, JC Yang, CM Armstrong, AP Lombard, ... Molecular cancer therapeutics 19 (8), 1708-1718, 2020 | 56 | 2020 |
| ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling C Liu, CM Armstrong, S Ning, JC Yang, W Lou, AP Lombard, J Zhao, ... Oncogene 40 (35), 5379-5392, 2021 | 26 | 2021 |
| Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer CM Armstrong, C Liu, L Liu, JC Yang, W Lou, R Zhao, S Ning, ... Clinical Cancer Research 26 (22), 6064-6074, 2020 | 17 | 2020 |
| Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells AP Lombard, W Lou, CM Armstrong, LS D'Abronzo, S Ning, CP Evans, ... Molecular cancer therapeutics 20 (10), 2061-2070, 2021 | 16 | 2021 |
| Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer JC Yang, P Xu, S Ning, LJ Wasielewski, H Adomat, SH Hwang, ... Oncogene 42 (9), 693-707, 2023 | 11 | 2023 |
| Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer AP Lombard, CM Armstrong, LS D'Abronzo, S Ning, AR Leslie, M Sharifi, ... Molecular cancer therapeutics 21 (4), 677-685, 2022 | 9 | 2022 |
| Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment S Ning, C Liu, W Lou, JC Yang, AP Lombard, LS D'Abronzo, N Batra, ... Molecular cancer therapeutics 21 (10), 1594-1607, 2022 | 8 | 2022 |
| Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models P Xu, JC Yang, S Ning, B Chen, C Nip, Q Wei, L Liu, OT Johnson, AC Gao, ... Pharmacological research 189, 106692, 2023 | 7 | 2023 |
| Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes S Ning, J Zhao, AP Lombard, LS D’Abronzo, AR Leslie, M Sharifi, W Lou, ... Communications Medicine 2 (1), 118, 2022 | 5 | 2022 |
| IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer AR Leslie, S Ning, CM Armstrong, LS D’Abronzo, M Sharifi, ZA Schaaf, ... Iscience 27 (2), 2024 | 2 | 2024 |
| Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer LS D’Abronzo, AP Lombard, S Ning, CM Armstong, AR Leslie, M Sharifi, ... American journal of clinical and experimental urology 10 (5), 299, 2022 | 2 | 2022 |
| Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer B Chen, P Xu, JC Yang, C Nip, L Wang, Y Shen, S Ning, Y Shang, ... Oncogene, 1-13, 2024 | 1 | 2024 |
| Therapeutic resistance models and treatment sequencing in advanced prostate cancer ZA Schaaf, S Ning, AR Leslie, M Sharifi, X Han, C Armstrong, W Lou, ... Cancers 15 (21), 5273, 2023 | 1 | 2023 |
| PD07-02 Targeting Wnt5a/Fzd2 signaling overcomes resistance to enzalutamide in advanced prostate cancer S Ning, C Liu, W Lou, A Lombard, L D'Abronzo, A Yu, C Evans, A Gao Journal of Urology 207 (Supplement 5), e98, 2022 | 1 | 2022 |
| Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer P Xu, JC Yang, B Chen, S Ning, X Zhang, L Wang, C Nip, Y Shen, ... Nature Communications 15 (1), 6626, 2024 | | 2024 |
| LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer S Ning, CM Armstrong, E Xing, AR Leslie, RY Gao, M Sharifi, ZA Schaaf, ... Cancer Research, 2024 | | 2024 |
| BET PROTEIN INHIBITORS AND USE THEREOF AC Gao, P Li, M Foster, R Larue, CM Armstrong, W Lou, S Ning, E Xing US Patent App. 18/548,844, 2024 | | 2024 |
| MP60-17 THERAPEUTIC RESISTANCE MODELS AND TREATMENT SEQUENCING IN ADVANCED PROSTATE CANCER Z Schaaf, S Ning, A Lombard, C Liu, W Lou, A Gao Journal of Urology 211 (5S), e1007, 2024 | | 2024 |
| MP05-11 PINK1 SIGNALING CONFERS OLAPARIB RESISTANCE BY ACTIVATING MITOCHONDRIAL FUNCTION IN ADVANCED PROSTATE CANCER CELLS A Gao, Z Schaaf, S Ning, A Leslie, M Sharifi, A Lombard, W Lou Journal of Urology 211 (5S), e47, 2024 | | 2024 |
| Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer C Liu, B Chen, P Xu, J Yang, C Nip, L Wang, Y Shen, S Ning, Y Shang, ... Research Square, 2024 | | 2024 |
Allen C GaoUniversity of Califormia Davis在 ucdavis.edu 的电子邮件经过验证
